Similarly in patients with NSCLC, among other cancers, receiving anti-PD-1 immunotherapy, lncRNA RP11-705C-15.3 levels have been considered a putative prognostic factor for the treatment outcome [137]. This evidence concerns the gene PDCD1 and cancer.